US 12,071,397 B2
Topical compositions for the treatment of dermatological disorders
Gary I. Weinberger, East Amherst, NY (US); H. Robert Nagel, Newton, MA (US); and Richard A. Brown, Danville, NH (US)
Assigned to Evologie LLC, Newton, MA (US)
Filed by EVOLOGIE LLC, Newton, MA (US)
Filed on Apr. 16, 2021, as Appl. No. 17/232,729.
Application 17/232,729 is a division of application No. 16/269,318, filed on Feb. 6, 2019, granted, now 11,021,440.
Application 16/269,318 is a continuation of application No. 14/126,275, granted, now 10,202,338, issued on Feb. 12, 2019, previously published as PCT/US2012/041895, filed on Jun. 11, 2012.
Claims priority of provisional application 61/499,523, filed on Jun. 21, 2011.
Prior Publication US 2021/0238131 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 279/14 (2006.01); A61K 9/107 (2006.01); A61K 31/194 (2006.01); A61K 31/198 (2006.01); A61K 31/223 (2006.01); A61K 31/60 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/32 (2006.01)
CPC C07C 279/14 (2013.01) [A61K 9/107 (2013.01); A61K 31/194 (2013.01); A61K 31/198 (2013.01); A61K 31/223 (2013.01); A61K 31/60 (2013.01); A61K 47/14 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01)] 20 Claims
 
1. A method of treating a subject with a dermatological disorder,
wherein the method comprises topically administering to the subject a pharmaceutical composition comprising a tripartite complex and an anti-melanogenic compound;
wherein the tripartite complex consists of L-arginine, azelaic acid, and salicylic acid; and
wherein the dermatological disorder is selected from the group consisting of post-inflammatory hyperpigmentation (PIH), low skin hydration, excess sebum production, and acne vulgaris.